Suppliers / Biocon

Biocon

India 2 duplicate records merged Updated 9 July 2026

Biocon is an API and finished-dose manufacturer based in India. It holds 69 active US drug master files and 29 valid CEPs. Its filings concentrate with US FDA, AIFA (IT) and EDE (AE). Its GMP standing is certified by ANVISA (Brazil), EMA and CDSCO (India), among 8 authorities. Its most recent recorded inspection, by US FDA, closed on 3 September 2025 as VAI.

69
active US DMFs
29
valid CEPs
12
registered plants 3 with an FDA FEI number
429
filings across 29 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
3 of 3 confirmed
Inspections
6 of 8 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 3 September 2025 VAI US FDA
  • 20 September 2024 VAI US FDA
  • 26 July 2024 VAI US FDA
  • 21 June 2024 VAI US FDA
  • 2 June 2023 NAI US FDA
  • 19 May 2023 NAI US FDA
  • 26 February 2020 VAI US FDA
  • 24 January 2020 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Bengaluru, United Arab Emirates Not on file
Iskandar Puteri, United Arab Emirates Not on file
Johor, United Arab Emirates Not on file
Bangalore, Colombia Not on file
EDGWARE, United Kingdom Not on file
Bangalore, India Not on file

6 further sites are on record.

What they file, and where

Molecule Regulators Docs
Rosuvastatin EDQM, SFDA (Saudi Arabia), US FDA 11
Everolimus EDQM, SFDA (Saudi Arabia), US FDA 10
Sitagliptin EDQM, SFDA (Saudi Arabia), US FDA 7
Tacrolimus EDQM, SFDA (Saudi Arabia), US FDA 7
Fingolimod EDQM, SFDA (Saudi Arabia), US FDA 6
Mycophenolate Mofetil EDQM, SFDA (Saudi Arabia), US FDA 5
Posaconazole SFDA (Saudi Arabia), US FDA 5
Simvastatin EDQM, SFDA (Saudi Arabia), US FDA 5
Fluvastatin Sodium EDQM 4
Atorvastatin SFDA (Saudi Arabia), US FDA 3
Show all 30 molecules on file
Deferasirox EDQM, SFDA (Saudi Arabia), US FDA 3
Fluvastatin US FDA 3
Linagliptin SFDA (Saudi Arabia), US FDA 3
Mycophenolic Acid EDQM, SFDA (Saudi Arabia), US FDA 3
Pioglitazone SFDA (Saudi Arabia), US FDA 3
Pravastatin EDQM, US FDA 3
Teriflunomide EDQM, SFDA (Saudi Arabia), US FDA 3
Dapagliflozin US FDA 2
Dasatinib SFDA (Saudi Arabia), US FDA 2
Lenalidomide SFDA (Saudi Arabia), US FDA 2
Micafungin SFDA (Saudi Arabia), US FDA 2
Mirabegron EDQM, US FDA 2
Orlistat SFDA (Saudi Arabia), US FDA 2
Repaglinide EDQM, US FDA 2
Rivaroxaban EDQM, US FDA 2
Sacubitril SFDA (Saudi Arabia), US FDA 2
Sirolimus SFDA (Saudi Arabia), US FDA 2
Vildagliptin SFDA (Saudi Arabia), US FDA 2
Anidulafungin US FDA 1
Apixaban US FDA 1

Also appears on these molecule pages

Show 14 more molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA 102 6
AIFA (IT) 68 None
EDE (AE) 31 None
CDSCO (India) 30 8
NPRA (MY) 30 None
EMA 29 9
ANVISA (Brazil) None 14
MHRA (UK) None 4
EAEU_EEC None 1
FDA (GH) None 1
INVIMA (CO) None 1

Comparing suppliers?

Choose your molecules and target markets. Biocon comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 1 active litigation matter is on record.
  • The most recent inspection outcome was VAI, on 3 September 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates